Trial Profile
Phase II/III, open-label, randomized, controlled, multiple-dose study of efficacy and safety of BMS-224818 as part of a quadruple drug regimen in first renal transplant recipients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Belatacept (Primary) ; Ciclosporin
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 31 Jul 2017 Results of intent-to-treat post hoc analysis over ten years published in the American Journal of Transplantation
- 03 Mar 2010 The US FDA's Cardiovascular and Renal Drugs Advisory Committee recommended approval of belatacept following a review of belatacept clinical development programme which included data from this trial, according to a Bristol-Myers Squibb media release.
- 28 Nov 2005 New trial record.